Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

Core Viewpoint - Sagimet Biosciences Inc. is actively engaging with investors through participation in two upcoming conferences, highlighting its focus on developing novel therapeutics for metabolic and fibrotic conditions [1][4]. Company Overview - Sagimet Biosciences is a clinical-stage biopharmaceutical company specializing in FASN inhibitors aimed at addressing dysfunctional metabolic and fibrotic pathways linked to the overproduction of palmitate [3]. - The company's lead product, denifanstat, has successfully met all primary endpoints in its Phase 2b FASCINATE-2 clinical trial for MASH and in a Phase 3 trial for moderate-to-severe acne in partnership with a licensee in China [3]. - Denifanstat is an oral medication taken once daily, and it is currently being tested in combination with resmetirom in a Phase 1 PK clinical trial for cirrhotic patients with F4-stage MASH [3]. - Another product, TVB-3567, is an oral FASN inhibitor under investigation in a Phase 1 first-in-human clinical trial for acne [3]. Upcoming Events - Sagimet will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, with a fireside chat scheduled for 10am ET [4]. - The company will also be featured at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, with a fireside chat at 9:20am ET [4].